@newsramp.comTonix Pharmaceuticals (NASDAQ: TNXP) expands TONMYA Medicare coverage to 32 million lives, reaching 58% of U.S. Medicare beneficiaries. Total covered lives now at 166 million. Sales force grows to 150 reps. #Fibromyalgia #Biotech
@newsramp.comRoth Capital Partners will host its 5th Annual Healthcare Opportunities Conference on Sept. 29, 2026, in New York City, bringing together 30+ public healthcare companies and top institutional investors for high-impact meetings and discussions. #Healthcare #Biotech
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, a novel drug candidate targeting the enzyme behind myelin destruction in MS. With ~3 million people affected globally and no cure in sight, new approaches are urgently needed. #MultipleSclerosis #Biotech
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) is advancing its 'AND-gated' BiTAC cancer platform following its NASDAQ debut in June 2026. Early preclinical data and key leadership hires signal the Swiss biotech is gaining momentum in oncology drug development. #Oncology #Biotech
@789.xyzSeminis.xyz Seed innovation, global agriculture, biotech breakthrough #Agritech #Biotech #GlobalFarming #Innovation #DomainSale
@newsramp.comLantern Pharma (NASDAQ: LTRN) is hosting a live webinar showcasing its Open-Medicine AI platform for drug development. CEO Panna Sharma covers market opportunity, platform demo, and growth roadmap. Launched as withZeta.ai, OMAI is expanding beyond rare cancers. #Biotech #AI
@newsramp.comLantern Pharma (NASDAQ: LTRN) is hosting a live webinar showcasing its Open-Medicine AI platform for drug development. CEO Panna Sharma covers market opportunity, platform demo, and growth roadmap. Launched as withZeta.ai, OMAI is expanding beyond rare cancers. #Biotech #AI
@newsramp.comKairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech
@newsramp.comKairos Pharma (NYSE: KAPA) CSO Neil Bhowmick will present KROS-101 solid tumor research and moderate a cancer drug resistance session at the Discovery on Target Conference in Boston, Sept. 30. #Oncology #BioTech
@newsramp.comAnnovis Bio ($ANVS) partners with Weave Bio to use AI in preparing its NDA for buntanetap, targeting Alzheimer's and Parkinson's. Phase 3 enrollment hit 862 patients, topping the 760 target. Data expected March 2027. #Biotech #Alzheimers
@newsramp.comAnnovis Bio ($ANVS) partners with Weave Bio to use AI in preparing its NDA for buntanetap, targeting Alzheimer's and Parkinson's. Phase 3 enrollment hit 862 patients, topping the 760 target. Data expected March 2027. #Biotech #Alzheimers
@newsramp.comUnbuzzd Wellness names Michael 'Zappy' Zapolin as CEO with a mandate to take the company public and launch a nationwide rollout of its hangover-relief beverage, unbuzzd(TM). Parent licensor Quantum BioPharma (NASDAQ: QNTM) stands to benefit via royalty agreements. #Biotech #IPO
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its Nasdaq debut. Parent company Xlife Sciences reports strong H1 progress across a portfolio backed by 416 patents. #Biotech #Oncology
@newsramp.comVERAXA Biotech (NASDAQ: VRXA) is advancing its oncology pipeline and securing industry partnerships after its June 2026 Nasdaq debut. Parent Xlife Sciences reports H1 portfolio progress across diagnostics, AI, and pharma, backed by 416 patents. #Oncology #Biotech
@andrearavalli.bsky.social👋 Andrea Ravalli · eToro Popular Investor
📊 Long-Term Multi-Asset Strategy:
• +190% cumulative return since 2020 (~17% CAGR)
• 3/10 Risk Score · 0% Leverage (1x real assets)
• Core: Healthcare & Biotech
#FinSky #Investing $LLY ABBV NOVO #Healthcare #Biotech #Dividends
@markfortner.bsky.socialBiotech's biggest challenge? Choosing the next project! 🤔 We need a new way to evaluate beyond just finances. The Ring of Fire helps us gauge confidence in literature, biology, and market potential for smarter, data-driven choices. 🔍💡 #Biotech #Innovation #PortfolioManagement #PM
@newsramp.comNanoViricides $NNVC has begun patient enrollment in its Phase II trial of NV-387 Oral Gummies for Ebola treatment in the Democratic Republic of Congo, marking a key clinical milestone for the nanomedicine company. #Ebola #Biotech
@newsramp.comRegentis Biomaterials' GelrinC implant shows ~100% greater KOOS improvement vs. microfracture at 2 years, as orthopedics shifts from pain management to structural cartilage repair. CE Mark approved; U.S. trial enrollment targets year-end 2026. #Orthopedics #BioTech
@newsramp.comRegentis Biomaterials' GelrinC hydrogel implant showed ~100% greater KOOS improvement vs. microfracture at 2 years. CE Mark approved in Europe, U.S. pivotal trial enrollment targeted for completion by end of 2026. Structural knee repair is gaining momentum. #Orthopedics #Biotech
@newsramp.comHelix BioPharma appoints four senior leaders to its Board, including a new Chair, as part of a major governance overhaul designed to accelerate its oncology pipeline and long-term growth strategy. #Biotech #Oncology